Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
IRRAS AB publishes Year End Report for the period January to December 2022 PR Newswire STOCKHOLM, Feb. 16, 2023 Commercial partnership underway to wrap up meaningful year of growth STOCKHOLM...
IRRAS AB publishes Year End Report for the period January to December 2022 PR Newswire STOCKHOLM, Feb. 16, 2023 Commercial partnership underway to wrap up meaningful year of growth STOCKHOLM...
IRRAflow System Confirmed to More Effectively Remove Collected Blood and Reduce Catheter Infection Rates than Passive Drainage in Head-to-Head Analysis PR Newswire STOCKHOLM, Feb. 13, 2023...
IRRAflow System Confirmed to More Effectively Remove Collected Blood and Reduce Catheter Infection Rates than Passive Drainage in Head-to-Head Analysis PR Newswire STOCKHOLM, Feb. 13, 2023...
IRRAS Receives US FDA 510(k) Clearance for its Next Generation IRRAflow Control Unit PR Newswire STOCKHOLM, Dec. 12, 2022 IRRAS received US FDA 510(k) clearance for its class II next-generation...
IRRAS Receives US FDA 510(k) Clearance for its Next Generation IRRAflow Control Unit PR Newswire STOCKHOLM, Dec. 12, 2022 IRRAS received US FDA 510(k) clearance for its class II next-generation...
IRRAS Announces Commercial Partnership with Medtronic in the United States for its IRRAflow® System PR Newswire STOCKHOLM, Nov. 14, 2022 IRRAS has signed a commercial agreement with Medtronic...
IRRAS Announces Commercial Partnership with Medtronic in the United States for its IRRAflow® System PR Newswire STOCKHOLM, Nov. 14, 2022 IRRAS has signed a commercial agreement with Medtronic...
IRRAS AB publishes Interim Report for the period January to September 2022 PR Newswire STOCKHOLM, Nov. 10, 2022 STOCKHOLM, Nov. 10, 2022 /PRNewswire/ -- Financial Runway Extended during Q3 as...
IRRAS AB publishes Interim Report for the period January to September 2022 PR Newswire STOCKHOLM, Nov. 10, 2022 STOCKHOLM, Nov. 10, 2022 /PRNewswire/ -- Financial Runway Extended during Q3 as...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 29.038 | 29.038 | 29.038 | 0 | 0 | DE |
| 4 | 0 | 0 | 29.038 | 29.038 | 29.038 | 0 | 0 | DE |
| 12 | 0 | 0 | 29.038 | 29.038 | 29.038 | 0 | 0 | DE |
| 26 | 0 | 0 | 29.038 | 29.038 | 29.038 | 0 | 0 | DE |
| 52 | 0 | 0 | 29.038 | 29.038 | 29.038 | 0 | 0 | DE |
| 156 | 0 | 0 | 29.038 | 29.038 | 29.038 | 1847 | 29.038 | DE |
| 260 | 0 | 0 | 29.038 | 29.038 | 29.038 | 1173 | 29.038 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
